title: Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.
abstract: Hepatitis C virus (HCV) is a significant global public health problem with >185 million infections worldwide. A series of genome-wide association studies (GWAS) has identified IL-28B polymorphisms as a predictor of sustained virologic response (SVR), as well as spontaneous clearance in chronic HCV genotype 1 patients. The objective of this work was to evaluate the prevalence of IL-28B rs12979860 and rs8099917 polymorphisms in Cuban chronic HCV patients. The study cohort included 73 chronic HCV patients treated with concomitant administration of CIGB-230 and nonpegylated IFN-α plus ribavirin (non-pegIFN-α/R) antiviral therapy. The genotype distribution of IL-28B rs12979860CC, -CT, and -TT was 29, 41, and 30%, respectively, and the distribution for rs8099917TT, -TG, and -GG was 63, 31, and 5%, respectively. The allele frequencies for rs12979860C and -T alleles were 51 and 49%, respectively, and for rs8099917G and -T alleles, the values were 21 and 79%, respectively. SVR rates were 55, 42, and 35% for rs12979860CC, -CT, and -TT, respectively, and 52, 30, and 25% for rs8099917TT, -GT, and -GG, respectively. The combined assessment of both single nucleotide polymorphisms (SNPs) resulted in 3 major genotypes (rs12979860CC/rs8099917TT, rs12979860CT/rs8099917TT, and rs12979860CT/rs8099917GG) with a frequency of 30.1, 21.9, and 20.5%, respectively. In patients with heterozygous variant rs12979860CT, the additional genotyping of rs8099917 contributed to increase the SVR rate. It is concluded that in Cuban HCV-infected patients, the responder homogeneous variant rs8099917TT is the most frequent genotype. The simultaneous genotyping of 2 IL-28B SNPs could improve the prediction of SVR contributing to better therapeutic decisions and treatment management.
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Daniel
authors.initials: D
authors.lastname: Palenzuela Gardón
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Isabel Alicia
authors.initials: IA
authors.lastname: Guillen
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Julio R
authors.initials: JR
authors.lastname: Fernández
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Hamlet
authors.initials: H
authors.lastname: Camacho
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Zurina Cinza
authors.initials: ZC
authors.lastname: Estevez
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Santiago
authors.initials: S
authors.lastname: Dueñas
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Liz
authors.initials: L
authors.lastname: Alvares-Lajonchere
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Yalena
authors.initials: Y
authors.lastname: Amador
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Gillian
authors.initials: G
authors.lastname: Martinez-Donato
authors.affiliation: Shanghai Biochip Company Limited/National Engineering Center for Biochip at Shanghai, Shanghai, China.
authors.forename: Junsong
authors.initials: J
authors.lastname: Han
authors.affiliation: Shanghai Biochip Company Limited/National Engineering Center for Biochip at Shanghai, Shanghai, China.
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Shanghai Biochip Company Limited/National Engineering Center for Biochip at Shanghai, Shanghai, China.
authors.forename: Xiaona
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Shanghai Biochip Company Limited/National Engineering Center for Biochip at Shanghai, Shanghai, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Juan Roca
authors.initials: JR
authors.lastname: Campaña
authors.affiliation: Center for Genetic Engineering and Biotechnology, Havana, Cuba; and.
authors.forename: Lidia I
authors.initials: LI
authors.lastname: Novoa
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D015331:Cohort Studies; D003462:Cuba; D005260:Female; D005787:Gene Frequency; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D019444:Vaccines, DNA / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D012254:Ribavirin; D019444:Vaccines, DNA; D014761:Viral Hepatitis Vaccines; C000589562:CIGB-230 vaccine; C000624353:interferon-lambda, human; D000095022:Interferon Lambda
keywords: IFN-α; SNP; SVR